Oral weight-loss medications could widen demand, but the bigger issue is whether coverage is becoming a must-have benefit or an unsustainable cost.
New GLP-1 weight-loss pills are arriving at a time when many employers are still trying to answer a more fundamental question: should these drugs be part of a competitive benefits package at all?
The category has already reshaped conversations around health coverage, recruiting, and employee expectations. A pill option may remove one barrier for workers hesitant about injections, but it could also increase pressure on organizations that have so far resisted broad coverage.
That pressure comes as adoption remains uneven. According to the 2025 Employer Health Benefits Survey from KFF, 19% of firms with 200 or more workers covered GLP-1 agonists for weight loss last year. Among employers with 5,000 or more workers, that figure rose to 43%.
The gap suggests many companies still view weight-loss drug coverage as a strategic choice rather than a standard offering.
“They started to do so to be competitive in the labor market,” said Paul Fronstin, director of health benefits research at the Employee Benefit Research Institute. “They were concerned about recruiting the right people and keeping them.”
And while benefits still matter in the talent market. the cost of keeping up is rising.
A benefits perk or a business risk?
For years, employers have used health benefits to attract and retain talent. GLP-1 drugs now test how far that strategy can stretch when demand is high and long-term costs are difficult to predict.
Many HR leaders are no longer debating whether the drugs matter. They are debating whether they can sustain them.
“Most HR leaders are not asking if GLP-1s matter anymore,” said Ferrin Williams, chief pharmacy officer at Scripta Insights. “Rather, they’re asking how to survive the cost curve.”
Fronstin explained that what makes GLP-1s different from many other expensive therapies is the scale of potential demand.
“The GLP-1, even though it's less money, it's still expensive and you're talking 50% of your population might be eligible for these. Right. Not just one or two people,” he said.
Read more: US employers diversify health plans amid rising costs
Additionally, Williams said fairness concerns also surface often. Leaders question whether covering high-profile weight-loss drugs could mean scaling back spending elsewhere. Others worry that once access is granted, it may be difficult to reverse course if costs continue climbing.
Fronstin said employers must also consider turnover. A company may absorb treatment costs today while the largest health savings emerge years later, potentially after the employee has moved on.
“You take a young obese person that doesn’t have any health conditions other than obesity,” he said. “At what point might they get diabetes or at what point might they start to have musculoskeletal issues?”
That uncertainty helps explain why smaller and mid-sized employers may move more cautiously than large organizations with greater scale and typically more expensive plans.
Pills may widen access, not solve the problem
Oral GLP-1s could draw interest from employees who dislike injections or see pills as an easier first step. Experts say convenience alone will not determine what happens next.
“GLP-1 pills are an important evolution in the category, but I would be careful about overstating their impact on total market growth,” Williams said. A meaningful share of pill use may come from members who otherwise would have used injectables, she added.
Instead, Williams said, the real drivers will be cost, access and tolerability. If pills are cheaper, easier to obtain or placed on preferred formulary tiers, uptake could accelerate. If side effects remain a concern or utilization controls stay tight, growth may be more modest.
That leaves employers facing a familiar problem: more employee interest without a guaranteed lower-cost solution.
Fronstin noted that pricing in the category has been changing quickly, making long-term planning difficult. Some employers not covering the drugs now could reconsider if prices fall further, he said. Others may conclude lower cash-pay options make formal coverage less necessary.
The shift toward targeted coverage
The better question may not be whether to cover GLP-1s, but how to cover them responsibly.
Rather than treating coverage as all-or-nothing, Fronstin and Williams pointed to more targeted models, including limiting access to higher-risk populations, requiring prior authorization, setting reassessment checkpoints, and pairing medication coverage with nutrition or behavioral support.
Read more: Frontline staff feel respected at work but exposed on benefits
Williams said organizations should avoid locking themselves into long-term policies while pricing, competition, and clinical evidence continue to evolve.
“Do not make a permanent decision based on a temporary market,” Williams said. “Prices, competition, clinical evidence, oral options, and employer norms are all evolving.”
Fronstin added that workforce makeup also matters. Companies with lower turnover or older populations may evaluate coverage differently than employers with younger or more transient workforces.
Employers that offer coverage often include lifestyle management programs to improve outcomes and help employees manage side effects, he said.
The most effective approach may be less about saying yes or no, and more about building a plan that can adapt as the market changes. As oral GLP-1 options expand and employee awareness grows, more employers may soon need a strategy, whether they’re ready or not.
